Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB-WT) EBIT (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed EBIT for 3 consecutive years, with -$34.0 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 36.9% to -$34.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$213.1 million through Dec 2025, up 64.05% year-over-year, with the annual reading at -$213.1 million for FY2025, 64.05% up from the prior year.
  • EBIT for Q4 2025 was -$34.0 million at Nuvation Bio, up from -$56.4 million in the prior quarter.
  • The five-year high for EBIT was -$20.2 million in Q1 2024, with the low at -$470.4 million in Q2 2024.
  • Average EBIT over 3 years is -$75.5 million, with a median of -$41.1 million recorded in 2024.
  • The sharpest move saw EBIT crashed 1700.1% in 2024, then skyrocketed 86.48% in 2025.
  • Over 3 years, EBIT stood at -$20.8 million in 2023, then tumbled by 158.95% to -$53.9 million in 2024, then skyrocketed by 36.9% to -$34.0 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$34.0 million, -$56.4 million, and -$63.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.